New drug hope for rare throat and thyroid cancers
NCT ID NCT07521670
First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times
Summary
This study tests a drug called sacituzumab tirumotecan in people with two rare cancers: adenoid cystic carcinoma (a type of salivary gland cancer) and papillary thyroid carcinoma that have returned or spread. About 68 participants will receive the drug through an IV twice a month. The main goal is to see if the drug shrinks tumors. This is an early-phase trial, so the focus is on safety and effectiveness, not a cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Cancer Center Hospital
Tokyo, Japan
-
National Cancer Center Korea
Gyeonggi-do, South Korea
-
National Cancer Centre Singapore
Singapore, Singapore
-
Sarawak General Hospital
Kuching, Sarawak, Malaysia
-
Seoul National University Hospital
Seoul, South Korea
-
Tan Tock Seng Hospital
Singapore, Singapore
-
University of Malaya Medical Center
Kuala Lumpur, Malaysia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill target multiple Hard-to-Treat cancers?
- Scientists mine 1,100 patient records to spot thyroid cancer return risks
- Robotic surgery through the mouth could eliminate neck scars in thyroid cancer patients
- AI assistant aims to ease thyroid cancer anxiety before surgery
- New drug cocktail targets genetic weakness in rare cancer
- New thyroid test aims to cut unnecessary surgeries